Xavier Hébuterne

S1451 Relationship Between Clinical and Histologic Findings With Tulisokibart Induction at Week 12 and Maintenance Dosing at Week 50 in the Phase 2 Randomized Controlled ARTEMIS-UC Study in Participants With Ulcerative Colitis

Brigid S. Boland, D. Christopher, Rupert W. Leong, Jarosław Leszczyszyn et autres

Determinants and influence of phase angle and its variation in HPN patients with intestinal failure

P. Caroli-Bosc, Nicolas Barbier, E. Eyraud, Lorenzo Gilli et autres

fr (code pays fourni par la source)

Blood proteomic signatures associated with disease activity in inflammatory bowel diseases

Maëva Veyssière, Nassim Hammoudi, Lionel Le Bourhis, Déborah Hassid et autres

fr, be, in, ca (code pays fourni par la source)

Mo1985: ACCEPTABILITY AND TOLERANCE OF RISANKIZUMAB TREATMENT ADMINISTERED VIA ON-BODY INJECTOR IN PATIENTS WITH CROHN’S DISEASE: RESULTS OF THE NATIONWIDE ACCEPT OBI STUDY

Anthony Buisson, Karim Gebara, Laurent Peyrin-Biroulet, Gilles Boschetti et autres

912: COMPARATIVE EFFICACY OF INFLIXIMAB AND VEDOLIZUMAB AFTER FAILURE OF A FIRST ANTI-TNF IN PATIENTS WITH ULCERATIVE COLITIS: A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL (EFFICACI)

Guillaume Bouguen, Maria Nachury, Stéphane Nancey, Yoram Bouhnik et autres

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

David T. Rubin, Jessica R. Allegretti, Julián Panés, Nicole Shipitofsky et autres

us, es, cn, ca, jp, fr, de, ua (code pays fourni par la source)

Activité physique et MICI

Xavier Hébuterne

fr (code pays fourni par la source)

Risankizumab for Ulcerative Colitis

Edouard Louis, Stefan Schreiber, Remo Panaccione, Peter Bossuyt et autres

be, de, ca, ch, us, gb, fr, nl, jp, cn, it (code pays fourni par la source)

Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study

S Bendaoud, Stéphane Nahon, Laurent Beaugerie, J.M. Gornet et autres

fr, us (code pays fourni par la source)

Long-term Outcome of Risankizumab in Crohn’s Disease: a Real-world GETAID Study

Mathurin Fuméry, Bénédicte Caron, Xavier Hébuterne, Romain Altwegg et autres

fr (code pays fourni par la source)

COMPARISON OF NORMAL VS INTENSIFIED VACCINE REGIMENS AGAINST PNEUMOCOCCUS IN CD PATIENTS UNDER BIOTHERAPY: A PROSPECTIVE, MULTICENTER, RANDOMIZED, OPEN-LABEL, PNEUMOMICI STUDY

Xavier Roblin, Stéphane Nancey, Xavier Hébuterne, Guillaume Savoye et autres

Prevalence of the Oral Corticosteroid Exposure and Excessive Use in Patients with Inflammatory Bowel Disease: Data from Four French Referral Centers of the International DICE Study

Stéphane Nancey, Xavier Hébuterne, Cyrielle Gilletta, Evguenia Hacques et autres

fr (code pays fourni par la source)